FDA approves Humacyte’s lab-grown blood vesselsnews2024-12-20T18:53:56+00:00December 20th, 2024|Endpoints News|
GSK’s Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survivalnews2024-12-20T16:37:07+00:00December 20th, 2024|Endpoints News|
Sofinnova outlines $550M fund after IPOs and M&A dealsnews2024-12-20T16:08:52+00:00December 20th, 2024|Endpoints News|
Applied Therapeutics CEO steps down after rare disease drug rejectionnews2024-12-20T15:44:47+00:00December 20th, 2024|Endpoints News|
Idorsia’s Tryvio deal delay; Galectin’s liver drug disappointsnews2024-12-20T15:16:16+00:00December 20th, 2024|Endpoints News|
Commure’s latest acquisition sends follow-up texts to patientsnews2024-12-20T13:00:23+00:00December 20th, 2024|Endpoints News|
Tracer Biotechnologies raises $10M, partners with AstraZenecanews2024-12-20T12:00:14+00:00December 20th, 2024|Endpoints News|
Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis’ kidney biotech poaches Sana CBOnews2024-12-20T12:00:02+00:00December 20th, 2024|Endpoints News|
Aadi starts from scratch as it sells assets, licenses ADCs and raises new fundsnews2024-12-20T11:58:29+00:00December 20th, 2024|Endpoints News|
Florida cancer biotech Syncromune raises $100M Series Anews2024-12-20T11:30:38+00:00December 20th, 2024|Endpoints News|
